Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 5;21(4):30.
doi: 10.1007/s11912-019-0783-5.

Evidence-Based Practice: Temozolomide Beyond Glioblastoma

Jason Chua  1 , Elizabeth Nafziger  1 , Denise Leung  2
Affiliations
Review

Evidence-Based Practice: Temozolomide Beyond Glioblastoma

Jason Chua et al. Curr Oncol Rep. .

Abstract

Purpose of review: Temozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma.

Recent findings: Temozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Temozolomide afforded less toxicity and comparable efficacy to radiation in high-risk low-grade gliomas and to platinum-based chemotherapy in pediatric high-grade gliomas. The success of temozolomide in promoting survival has expanded beyond glioblastoma to benefit patients with non-glioblastoma tumors. Identifying practical biomarkers for predicting temozolomide susceptibility, and establishing complementary agents for chemosensitizing tumors to temozolomide, will be key next steps for future success.

Keywords: Bevacizumab; DIPG; Ependymoma; GBM in the elderly; Low grade glioma; Pilocytic astrocytoma; Pleomorphic xanthoastrocytoma; Temozolomide.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Oncologist. 2000;5(2):144-51 - PubMed
    1. Neuro Oncol. 2002 Jan;4(1):39-43 - PubMed
    1. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
    1. Br J Cancer. 2006 Nov 6;95(9):1155-60 - PubMed
    1. Neuro Oncol. 2007 Apr;9(2):161-8 - PubMed

MeSH terms

Substances

LinkOut - more resources